<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718937</url>
  </required_header>
  <id_info>
    <org_study_id>BTA585-003</org_study_id>
    <nct_id>NCT02718937</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study</brief_title>
  <official_title>A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biota Pharma Europe Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaxart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the antiviral activity of oral BTA-C585
      compared to placebo in healthy volunteers after intranasal challenge with RSV-A Memphis 37b
      virus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) viral load of RSV-A Memphis 37b</measure>
    <time_frame>Days 2-13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of total RSV symptom scores</measure>
    <time_frame>Days 1-13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Screening to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Respiratory Syncytial Virus (RSV) Infection</condition>
  <arm_group>
    <arm_group_label>BTA-C585</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BTA-C585 100 mg oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTA-C585 oral capsule</intervention_name>
    <arm_group_label>BTA-C585</arm_group_label>
    <other_name>BTA585</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo capsules</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female

          2. Between 18 to 50 years old

          3. Body mass index of 18 to 30 kg/m2

        Exclusion Criteria:

          1. Acute or chronic medical illness

          2. Abnormal lung function Positive for HIV, Hepatitis B or C

          3. Any significant abnormality of the nose or nasopharynx
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Novotney-Barry</last_name>
    <role>Study Director</role>
    <affiliation>Aviragen Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biota Investigational Site</name>
      <address>
        <city>London</city>
        <zip>E1 2AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Viral diseases</keyword>
  <keyword>Antiviral</keyword>
  <keyword>Paramyxoviridae infections</keyword>
  <keyword>RSV</keyword>
  <keyword>Aviragen Therapeutics, Inc.</keyword>
  <keyword>Aviragen Therapeutics</keyword>
  <keyword>Aviragen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

